Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   JOURNAL OF CURRENT OPHTHALMOLOGY   2006 , Volume 19 , Number 3; Page(s) 22 To 28.
 
Paper: 

TISSUE PLASMINOGEN ACTIVATOR VERSUS ASPIRIN IN CENTRAL RETINAL VEIN OCCLUSION

 
 
Author(s):  FARAHVASH M.T., MIRSHAHI A., FAGHIHI H., ALAMI HARANDI Z., RIAZI ESFAHANI M., NILI AHMADABADI M., MOVASAT M., AGHSAIE FARD M.*, LASHEYEI A.R., JAVADIAN A., KARKHANEH R., MORADI MOGHADAM MARZIEH, TABATABAEI S.A., MANSOURI M.R.
 
* FARABI EYE HOSPITAL, TEHRAN UNIVERSITY OF MEDICAL SCIENCES
 
Abstract: 

Purpose: To compare the effect of tissue plasminogen activator (TPA) and aspirin in patients with central retinal vein occlusion.
Methods: A prospective interventional study was conducted on patients with central retinal vein occlusion of less than 28 days' duration. Patients in the TPA group received 100
mg intravitreal tissue plasminogen activator and the patients who declined intravitreal injection were considered as Aspirin group. Patients were followed up for 6 months.
Results: sixty five patients were enrolled, 19 in the TPA group and 46 in the Aspirin group. The mean 6-month change in visual acuity for TPA-treated patients was -0.29
±0.42 (range: -1.4 to +0.5) while in the Aspirin group, it was 0.28±0.79 with a range of -1 to +2.5. TPA group had a significantly better visual improvement in comparison to Aspirin group (P<0.0005).

Conclusion: Intravitreal tissue plasminogen activator can be injected safely and easily. Patients treated with intravitreal tissue plasminogen activator within 28 days of the onset of central retinal vein occlusion are more likely to improve visual acuity.

 
Keyword(s): CENTRAL RETINAL VEIN OCCLUSION, TISSUE PLASMINOGEN ACTIVATOR, VISUAL ACUITY, NEOVASCULARIZATION OF IRIS
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 106
 
Latest on Blog
Enter SID Blog